Birmpili Panagiota, Benson Ruth A, Gwilym Brenig, Nandhra Sandip, Al-Saadi Nina, Ambler Graeme K, Blair Robert, Bosanquet David, Dattani Nikesh, Hitchman Louise, Hurndall Katherine, Machin Matthew, Onida Sarah, Saratzis Athanasios, Shalhoub Joseph, Shelmerdine Lauren, Singh Aminder A
Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Department of Vascular, Endovascular & Transplant Surgery, University of Otago, Christchurch, New Zealand.
EJVES Vasc Forum. 2024 Sep 19;62:64-71. doi: 10.1016/j.ejvsvf.2024.08.002. eCollection 2024.
The first COVID-19 pandemic wave was a period of reduced surgical activity and redistribution of resources to only those with late stage or critical presentations. This Vascular and Endovascular Research Network COVID-19 Vascular Service (COVER) study aimed to describe the six-month outcomes of patients who underwent open surgery and or endovascular interventions for major vascular conditions during this period.
In this international, multicentre, prospective, observational study, centres recruited consecutive patients undergoing vascular procedures over a 12-week period. The study opened in March 2020 and closed to recruitment in August 2020. Patient demographics, procedure details, and post-operative outcomes were collected on a secure online database. The reported outcomes at 30 days and six months were post-operative complications, re-interventions, and all cause in-hospital mortality rate. Multivariable logistic regression was used to assess factors associated with six-month mortality rate.
Data were collected on 3 150 vascular procedures, including 1 380 lower limb revascularisations, 609 amputations, 403 aortic, 289 carotid, and 469 other vascular interventions. The median age was 68 years (interquartile range 59, 76), 73.5% were men, and 1.7% had confirmed COVID-19 disease. The cumulative all cause in-hospital, 30-day, and six-month mortality rates were 9.1%, 10.4%, and 12.8%, respectively. The six-month mortality rate was 32.1% (95% CI 24.2-40.8%) in patients with confirmed COVID-19 compared with 12.0% (95% CI 10.8-13.2%) in those without. After adjustment, confirmed COVID-19 was associated with a three times higher odds of six-month death (adjusted OR 3.25, 95% CI 2.18-4.83). Increasing ASA grade (3-5 . 1-2), frailty scores 4-9, diabetes mellitus, and urgent and or immediate procedures were also independently associated with increased odds of death by six months, while statin use had a protective effect.
During the first wave of the pandemic, the six-month mortality rate after vascular and endovascular procedures was higher compared with historic pre-pandemic studies and associated with COVID-19 disease.
新冠疫情的第一波期间,外科手术活动减少,资源仅重新分配给那些处于晚期或危急状态的患者。这项血管与血管内研究网络新冠血管服务(COVER)研究旨在描述在此期间因主要血管疾病接受开放手术和/或血管内介入治疗的患者的六个月预后情况。
在这项国际多中心前瞻性观察性研究中,各中心招募在12周内连续接受血管手术的患者。该研究于2020年3月开始,2020年8月结束招募。患者人口统计学信息、手术细节和术后结果通过一个安全的在线数据库收集。报告的30天和六个月时的结果为术后并发症、再次干预以及全因住院死亡率。采用多变量逻辑回归评估与六个月死亡率相关的因素。
共收集了3150例血管手术的数据,包括1380例下肢血管重建术、609例截肢术、403例主动脉手术、289例颈动脉手术以及469例其他血管介入手术。中位年龄为68岁(四分位间距59, 76),73.5%为男性,1.7%确诊感染新冠病毒。累积全因住院死亡率、30天死亡率和六个月死亡率分别为9.1%、10.4%和12.8%。确诊感染新冠病毒的患者六个月死亡率为32.1%(95%可信区间24.2 - 40.8%),未感染新冠病毒的患者为12.0%(95%可信区间10.8 - 13.2%)。调整后,确诊感染新冠病毒与六个月死亡几率高出三倍相关(调整后的比值比3.25,95%可信区间2.18 - 4.83)。美国麻醉医师协会(ASA)分级增加(3 - 5级对比1 - 2级)、虚弱评分4 - 9分、糖尿病以及急诊和/或即刻手术也与六个月死亡几率增加独立相关,而使用他汀类药物具有保护作用。
在疫情的第一波期间,与疫情前的历史研究相比,血管和血管内手术后的六个月死亡率更高,且与新冠病毒感染有关。